Patient | Treatment and clinical course | Dual energy X-ray absorptiometry (DXA) T-scoresa | Additional imaging | Bone resorption and formation markers/biochemical indices | Inflammatory markers | Biopsy data |
---|---|---|---|---|---|---|
1 | Intravenous zoledronic acid infusions NED; progressive back pain requiring kyphoplasty | T-scores: Lumbar spine, −2.1 Left femoral neck, − 1.2 Left total hip, −0.4 Right femoral neck, − 1.7 Right total hip, − 0.8 | MRI: Multilevel compression fractures of T12-L5 vertebral bodies; bilateral posterolateral rib fractures; multiple nondisplaced pelvic fractures superimposed on underlying osteopenia. | CTX: 1038 pg/mL (↑) bsALP: 11.6 μg/L Ca: 9.5 mg/dL 25OHD: 48 ng/mL | CRP: 1.0 mg/dL (↑) ESR 12 mm/h | Transiliac bone biopsy: Reduced cortical and trabecular thickness; no osteoblastic activity; increased eroded surface and osteoclastic resorptive activity. |
2 | Denosumab q6mo Progressive metastatic disease requiring hospice care; now deceased | T-scores: Left femoral neck, − 1.5 Left total hip, 0.1 | VFA: Multiple wedge deformities 16.8% in T6, 13.6% in T7, 11.2% in T8, 18% in T9, 4.1% in T10, 6.9% in T12, 13.2% in L1. CT chest 1/17: New compression deformity of the superior endplates of T2-T5 vertebral bodies | CTX: 537 pg/mL bsALP: 13.1 μg/L Ca: 8.9. mg/dL 25OHD: 37 ng/mL | N/A | N/A |
3 | Conservative management with calcium and vitamin D optimization NED, pain free | T-scores: L-spine, − 0.9 Left femoral neck, − 1.8 Left total hip, − 1.2 | CT scan: T12 compression fracture with evolving compression deformity at T11; biconcave deformities of lumbar vertebrae | CTX: 335 pg/mL bsALP: 8.7 μg/L Ca: 9.4. mg/dL 25OHD: 18 ng/mL (↓) | N/A | N/A |
4 | Systemic oral steroids Adalimumab NED; improved inflammatory arthritis but progressive left shoulder pain and lack of mobility; no additional resorptive lesions | T-scores: L-spine, − 1.0 Left femoral neck, − 1.2 Left total hip, 0.2 1/3 radius, − 1.9 | MRI shoulder: Severe erosive changes of the glenohumeral articulation | CTX: 589 pg/mL (↑) bsALP: 18 μg/L (↑) Ca: 9.4. mg/dL 25OHD: 52 ng/mL | CRP: 2.7 mg/dL (↑) ESR: 69 mm/h (↑) | No evidence of melanoma (S100, HMB-45 and melan-A stains negative). Trabecular bone with bone marrow fibrosis and a scattered, mixed inflammatory cell infiltration. |
5 | Systemic oral steroids Progressive, metastatic disease; limited response to steroids, currently in hospice | N/A | Hand X-ray: Loss of ossific densities related to the capitate and also hamate, loss of cortical outline of the capitate and hamate | CTX: 877 pg/mL (↑) bsALP: 24 μg/L (↑) Ca: 8.8 mg/dL 25OHD: 51.8 | CRP: 13.5 mg/L (↑) ESR: 31 mm/h (↑) | N/A |
6 | NSAIDs, Intraarticular corticosteroids Progressive, metastatic disease; good rheumatologic response to steroids, currently on carboplatin pemetrexed and bevacizumab | T-scores: L- spine, 0.8 Left femoral neck, 0. 0 Left total hip, 0.8 | MRI clavicle: Acromioclavicular joint arthrosis with disproportionate bone marrow edema affecting the distal, no visible fracture | CTX: 681 pg/mL (↑) bsALP: 17 μg/L (↑) Ca: 8.8 mg/dL 25OHD: 22 ng/mL (↓) | CRP: 2.0 mg/dL (↑) ESR: 32 mm/h (↑) | N/A |